显微乳房再造加速康复外科路径的系统评价与荟萃分析
该研究系统检索截至2016年6月的文献,纳入4项原始研究共676例患者,比较显微乳房再造中加速康复外科(ERAS)路径与常规路径的结局。荟萃分析显示ERAS组住院时间显著缩短(平均差-1.23天,95%CI -1.50至-0.96,P<0.001),且未增加30天术后并发症。
要点
- ERAS路径可使显微乳房再造患者住院时间平均缩短1.23天。
- ERAS不增加30天术后并发症,包括皮瓣部分/完全丢失、血肿、感染等。
- 现有证据限于4项原始研究,需更多高质量研究验证。
核心结论
- 显微乳房再造中ERAS路径与住院时间缩短相关,且不增加术后并发症。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、Embase、Cochrane、Scopus和Web of Science截至2016年6月的研究。
- 最终纳入4项原始研究,共676例患者。
主要发现
- ERAS组住院时间显著短于对照组(平均差-1.23,95%CI -1.50至-0.96,P<0.001,I²=0%,随机效应模型)。
- 30天术后并发症无显著变化:皮瓣部分丢失(P=0.44)、皮瓣完全丢失(P=0.91)、乳房血肿(P=0.69)、供区感染(P=0.53)、尿路感染(P=0.29)、肺炎(P=0.42)。
临床怎么用
- 在显微乳房再造中可考虑实施ERAS路径以缩短住院时间,且不增加短期并发症风险。
局限性
- 纳入研究数量少(仅4项),证据等级有限。
- 检索截止2016年6月,未涵盖后续研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The enhanced recovery after surgery pathway was introduced in 1997 as a multimodal approach to reduce preventable postoperative harm and shorten hospital length of stay. However, there is yet no widely accepted enhanced recovery after surgery protocol for microsurgical breast reconstruction. The authors conducted a systematic review and meta-analysis of the current literature on enhanced recovery after surgery for microsurgical breast reconstruction with regard to postoperative length of stay and morbidity. METHODS: The PubMed, Embase, Cochrane, Scopus, and Web of Science databases were searched for all studies published before June of 2016 containing original data on enhanced recovery after surgery in microsurgical breast reconstruction in relation to postoperative length of stay and morbidity. Studies were screened using eligibility criteria. Meta-analysis, odds ratio, and 95 percent confidence interval were used to pool acquired data. RESULTS: The initial search identified 86 studies. Two independent screeners identified four original articles with a total of 676 patients. Length of stay was significantly shorter for patients on an enhanced recovery after surgery pathway (mean difference, -1.23; 95 percent CI, -1.50 to -0.96; p < 0.001; I = 0 percent; random effects model). Enhanced recovery was not associated with changes in 30-day postoperative morbidity; specifically, no significant difference was observed in rates of partial flap loss (p = 0.44), total flap loss (p = 0.91), breast hematoma (p = 0.69), donor-site infection (p = 0.53), urinary tract infection (p = 0.29), and pneumonia (p = 0.42). CONCLUSION: The authors' review suggests that enhanced recovery after surgery in microsurgical breast reconstruction is associated with a reduced length of stay, and is not associated with increased postoperative morbidity.
引用
- Sebai ME, Siotos C, Payne RM, et al. Enhanced Recovery after Surgery Pathway for Microsurgical Breast Reconstruction: A Systematic Review and Meta-Analysis. Plast Reconstr Surg. 2019. PMID: 30589825. doi:10.1097/PRS.0000000000005300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。